Ks Cheung

Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection

Chronic hepatitis B (CHB) cannot be completely eradicated due to the presence of covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes. While quantification of intrahepatic cccDNA requires liver biopsies, serological markers can be non‐invasive alternatives to reflect intrahepatic viral replicative activity. Recently, hepatitis B core‐related antigen (HBcrAg) has been advocated as a novel serum marker for disease monitoring and prognostication of CHB.

Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B

Factors influencing changes in liver stiffness measurements during long‐term nucleoside analogue therapy for chronic hepatitis B (CHB) have not been thoroughly investigated.

Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study

The temporal relationship between nucleoside analogue therapy for chronic hepatitis B (CHB) and liver cancer development has not been evaluated at a population level.

A Territory-Wide Study on the Seroprevalence of Hepatitis B Virus in the General Population after Universal Hepatitis B Immunization ERA in Hong Kong, China

Poster Presentations: Viral hepatitis: Hepatitis A, B, D, E – clinical (except therapy): no. THU-162

A population-based study on the seroprevalence of viral hepatitis in Hong Kong, China

This journal suppl. entitled: Conference Abstracts: 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, JapanAbstracts of the 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japans of the 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan Asian Pacific Association for the Study of the Liver 2016 Presidential PlenaryThis journal suppl. entitled: Conference Abstracts: 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, JapanThis journal suppl. entitled: Conference Abstracts: 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan

Determinants for persistent fibrosis during nucleoside analogue therapy in chronic hepatitis B

This journal suppl. entitled: Conference Abstracts: 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, JapanAbstracts of the 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japans of the 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan Asian Pacific Association for the Study of the Liver 2016 Presidential PlenaryThis journal suppl. entitled: Conference Abstracts: 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, JapanThis journal suppl. entitled: Conference Abstracts: 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan

Relationship between HCC and serum markers in NA-treated patients with undetectable HBV DNA

This journal suppl. entitled: Conference Abstracts: 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, JapanAbstracts of the 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japans of the 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan Asian Pacific Association for the Study of the Liver 2016 Presidential PlenaryThis journal suppl. entitled: Conference Abstracts: 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, JapanThis journal suppl. entitled: Conference Abstracts: 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan

Relationship between hepatocellular carcinoma development and serum viral markers in patients with undetectable serum HBV DNA level while on nucleos(t)ide analogues

Editor Masatoshi Kudo, OsakaMany studies report high response rates in patients with advanced HCC receiving HAIC, and clinical responses translate to survival benefits. Therefore, prediction of an antitumor response is important in selecting appropriate treatments. There are no proven post-sorafenib therapeutic procedures or procedures for HCC patients with poor liver function, and HAIC is one of the few options for patients in these situations. Despite studies showing its effectiveness, the use of HAIC for treatment of advanced HCC is unclear because convincing data from large-scale randomized clinical trials are lacking. For HAIC to become a standard treatment for HCC, such trials must establish its efficacy compared with other HCC therapies; prediction of antitumor response in HAIC may aid trial design, and a multi-center, open-label, randomized clinical trial of HAIC in advanced HCC is in progress. Optimization of HCC treatment protocols and regimens is also required.

Longitudinal serologic profiles up to 5 years in hepatitis B surface antigen-negative chronic hepatitis B

Enhance your working knowledge of state-of-the-art practices in the endoscopic management of patients with advanced cirrhosis, biliary tract disease, chronic cholestatic conditions, and other liver diseases—both before and after liver transplantation. The course will cover fundamental issues related to the quality and safety of endoscopic practice in the patient with liver disease, including safe administration of sedation as it relates to disease-specific issues such as coagulopathy. Participants will learn about management and prevention of variceal hemorrhage, as well as advanced endoscopic techniques such as cholangioscopy for biliary disease.